RiverVest Venture Partners

Investing in Life Science Innovation

RiverVest Venture Partners® is a venture capital firm focused on identifying and shaping early-stage life science companies to create significant shareholder value. With hands-on, high-level expertise and financial resources, RiverVest supports entrepreneurs by helping them achieve near-term objectives that position their companies for exit.

VC Partner as Sounding Board

Experience, steady leadership, a willingness to drive change, and a deep understanding of the growing pains of a start-up — these are a few of the benefits CEO Joe Army cites when discussing the role of Salient’s Chairman of the Board Jay Schmelter, who is also a managing director of RiverVest.

Anatomy of a Biopharmaceutical Deal

It was the perspicacity of team members J. Gordon Foulkes and Niall O’Donnell in shepherding pharmaceuticals from gene discovery to clinical trials that attracted entrepreneur Nicholas Dean, Ph.D., to partnering with RiverVest. The three met through ‘BioBrits’, a networking community in San Diego.

Venturing Into the Ear Frontier

Otonomy’s genesis has all the makings of a biopharmaceutical legend. Jay Lichter, Ph.D., managing director of Avalon Ventures, was driving down Prospect Street in La Jolla, Calif. one afternoon in January 2008 when he was struck not by a great entrepreneurial idea, but rather an unbearable dizziness.

St. Mary Medical Center and Centerre Healthcare Partner in Opening New Inpatient Rehabilitation Specialty Hospital

State-of-the-art facility to be first free-standing rehabilitation hospital in Bucks County

LANGHORNE, PA, April 29, 2013 – St. Mary Medical Center in Langhorne, PA, in partnership with Centerre Healthcare Corporation, headquartered in Nashville, TN, today announced plans for a newly designed acute rehabilitation hospital, the first specialty hospital of its kind in Bucks County.

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

New claim will help physicians better guide treatment with P2Y12 Inhibitors

April 16, 2013, San Diego, CA – Accumetrics, Inc., developer of the market-leading VerifyNow® System, announced an expansion in the intended use for the CE marked VerifyNow P2Y12 Test. Physicians can now use the test results to assess whether a patient may be at greater risk for both bleeding or ischemic events, as an aid to manage therapeutic treatment decisions and accurately assess the antiplatelet effect from P2Y12 inhibitors (such as clopidogrel, prasugrel and ticagrelor).

Mercy Breaks Ground on New Rehabilitation Hospital

Springfield, MO. (April 2, 2013) — Rehabilitation services in the Ozarks will get a major upgrade, as crews begin work on the new Mercy Rehabilitation Hospital Springfield.

The $28 million, 63,000 square foot facility will have 60 beds and provide inpatient rehabilitation for patients who are recovering from strokes, brain or spinal cord injuries, amputations, complex orthopedic injuries and other conditions. Construction is estimated to take about a year.